bucindolol
Small moleculeexperimental
Bucindolol is a non-selective beta blocker with additional weak alpha-blocking properties and intrinsic sympathomimetic activity in some model systems but not in human hearts. It was under review by the FDA in the United States for the treatment of heart failure in 2009, but was rejected due to issues pertaining to integrity of data submitted. — Wikipedia
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2014 (NCT01970501)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Beta-1 adrenergic receptorANTAGONIST
ADRB1 antagonist
- Adrenergic receptor alpha-1ANTAGONIST
Adrenergic receptor alpha-1 antagonist
- Beta-2 adrenergic receptorANTAGONIST
Beta-2 adrenergic receptor antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)(Cc1c[nH]c2ccccc12)NCC(O)COc1ccccc1C#N- Mol. weight
- 363.46 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL321582 ↗
- WikipediaBucindolol ↗
- ChEMBLCHEMBL2107546 ↗
Also known as
- benzonitrile, 2-(2-hydroxy-3-((2-(1h-indol-3-yl)-1,1-dimethylethyl)amino)propoxy)-, monohydrochloride
- bucindolol
- bucindolol
- bucindolol
- bucindolol
- bucindolol hcl
- bucindolol hcl
- bucindolol hydrochloride
- bucindolol hydrochloride
- bucindolol hydrochloride
- bucindolol hydrochloride
- mj 13105
- mj-13105-1
- mj-13105-1
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01970501 | Phase 2 | Apr 1, 2014 | Arca Biopharma, Inc., Duke University, Medtronic |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Arca Biopharma, Inc. | For profit | 1 | 1 | 1 | 2014 |
| Duke University | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Medtronic | For profit | 1 | 0 | 1 | 2014 |
3 organizations
Page 1 / 1